𝔖 Bobbio Scriptorium
✦   LIBER   ✦

An evaluation of the cardiotoxicity of imatinib mesylate

✍ Scribed by Antonio Luiz Ribeiro; Milena Soriano Marcolino; Henrique N.S. Bittencourt; Márcia M. Barbosa; Maria do Carmo P. Nunes; Vitor Fonseca Xavier; Nelma C.D. Clementino

Publisher
Elsevier Science
Year
2008
Tongue
English
Weight
111 KB
Volume
32
Category
Article
ISSN
0145-2126

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Imatinib mesylate for lymphocytic varian
Imatinib mesylate for lymphocytic variant of hypereosinophilic syndrome
✍ Grzegorz Helbig 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 427 KB 👁 2 views

## Imatinib mesylate for lymphocytic variant of hypereosinophilic syndrome To the editor: With a great interest I read a paper by Christoforidou et al. showing the high efficacy of imatinib mesylate (IM) in a patient with L-HES and undetectable FIP1L1-PDGFRA (F/P) fusion transcript. However, afte

Imatinib mesylate in Philadelphia chromo
Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood
✍ E. Anders Kolb; Qiulu Pan; Marc Ladanyi; Peter G. Steinherz 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 177 KB 👁 1 views

## Abstract ## BACKGROUND Initial treatment for adult patients with Philadelphia chromosome‐positive (Ph[+]) chronic myelogenous leukemia (CML) now includes imatinib mesylate. However, to our knowledge, there are few data regarding imatinib safety, efficacy, and response monitoring in patients age

Imatinib mesylate as a cause of acute li
Imatinib mesylate as a cause of acute liver failure
✍ Timothy J.S. Cross; Catherine Bagot; Bernard Portmann; Julia Wendon; D. Gillett 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB 👁 2 views

A 46-year-old patient diagnosed with chronic myeloid leukemia in whom cytogenetic and molecular remission had never been achieved was commenced on Imatinib Mesylate (Gleevecâ, Novartis Pharmaceuticals Corp., East Hanover, NJ). After 18 months of treatment, she developed abnormal liver function tests